Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | BCR | P11274 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1433262 | 0.94 | ABL1 (0.52) | ABL1BCRCYP2C9HRH3SMN1; SMN2 | |
| SCHEMBL1433672 | 0.94 | ABL1 (0.52) | ABL1BCRCYP2C9HRH3SMN1; SMN2 | |
| SCHEMBL1433623 | 0.94 | ABL1 (0.51) | ABL1BCRCYP2C9HRH3SMN1; SMN2 | |
| SCHEMBL1433597 | 0.93 | ABL1 (0.51) | ABL1BCRCYP2C9HRH3SMN1; SMN2 | |
| SCHEMBL1433738 | 0.93 | ABL1 (0.53) | ABL1BCRCYP2C9HRH3SMN1; SMN2 | |
| SCHEMBL1433409 | 0.93 | ABL1 (0.51) | ABL1BCRCYP2C9HRH3SMN1; SMN2 | |
| SCHEMBL4322180 | 0.93 | ABL1 (0.57) | ABL1BCRCYP2C9HRH3SMN1; SMN2 | |
| SCHEMBL1434078 | 0.92 | ABL1 (0.51) | ABL1BCRCYP2C9HRH3SMN1; SMN2 | |
| SCHEMBL1433298 | 0.92 | ABL1 (0.52) | ABL1BCRCYP2C9HRH3SMN1; SMN2 | |
| SCHEMBL1434156 | 0.92 | ABL1 (0.52) | ABL1BCRCYP2C9HRH3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300436-B1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2018-07-18 | — | — | EP | claimed |
| US-8809337-B2 | Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-08-19 | — | — | US | claimed |
| US-20130203770-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-08-08 | — | — | US | claimed |
| US-20110118278-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-19 | — | — | US | claimed |
| EP-2300436-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | Nerviano Medical Sciences S.r.l. (IT) | 2011-03-30 | — | — | EP | claimed |
| WO-2009138440-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-11-19 | — | — | WO | claimed |
| EP-2300436-B1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2018-07-18 | — | — | EP | disclosed |
| US-8809337-B2 | Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-08-19 | — | — | US | disclosed |
| US-20130203770-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-08-08 | — | — | US | disclosed |
| US-20110118278-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203770-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | DMPK, DCK, MAP3K19 | ABL1 556/4885BCR 600/4885CYP2C9 326/4885 |
| US-20110118278-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | DMPK, DCK, MAP3K19 | ABL1 556/4885BCR 600/4885CYP2C9 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.